195 related articles for article (PubMed ID: 29870556)
1. A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression.
Blasco H; Patin F; Descat A; Garçon G; Corcia P; Gelé P; Lenglet T; Bede P; Meininger V; Devos D; Gossens JF; Pradat PF
PLoS One; 2018; 13(6):e0198116. PubMed ID: 29870556
[TBL] [Abstract][Full Text] [Related]
2. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
[TBL] [Abstract][Full Text] [Related]
3. Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients.
Corona G; Cannizzaro R; Miolo G; Caggiari L; De Zorzi M; Repetto O; Steffan A; De Re V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518896
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of targeted metabolomics: dominance-based rough set approach versus orthogonal partial least square-discriminant analysis.
Blasco H; Błaszczyński J; Billaut JC; Nadal-Desbarats L; Pradat PF; Devos D; Moreau C; Andres CR; Emond P; Corcia P; Słowiński R
J Biomed Inform; 2015 Feb; 53():291-9. PubMed ID: 25499899
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression.
Blasco H; Nadal-Desbarats L; Pradat PF; Gordon PH; Madji Hounoum B; Patin F; Veyrat-Durebex C; Mavel S; Beltran S; Emond P; Andres CR; Corcia P
Eur J Neurol; 2016 Feb; 23(2):346-53. PubMed ID: 26508442
[TBL] [Abstract][Full Text] [Related]
6. Pharmacometabolomics applied to low-dose interleukin-2 treatment in amyotrophic lateral sclerosis.
Alarcan H; Bruno C; Emond P; Raoul C; Vourc'h P; Corcia P; Camu W; Veyrune JL; Garlanda C; Locati M; Juntas-Morales R; Saker S; Suehs C; Masseguin C; Kirby J; Shaw P; Malaspina A; De Vos J; Al-Chalabi A; Leigh PN; Tree T; Bensimon G; Blasco H
Ann N Y Acad Sci; 2024 Jun; 1536(1):82-91. PubMed ID: 38771698
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry.
Blasco H; Corcia P; Pradat PF; Bocca C; Gordon PH; Veyrat-Durebex C; Mavel S; Nadal-Desbarats L; Moreau C; Devos D; Andres CR; Emond P
J Proteome Res; 2013 Aug; 12(8):3746-54. PubMed ID: 23859630
[TBL] [Abstract][Full Text] [Related]
8. Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism.
Patin F; Corcia P; Vourc'h P; Nadal-Desbarats L; Baranek T; Goossens JF; Marouillat S; Dessein AF; Descat A; Madji Hounoum B; Bruno C; Leman S; Andres CR; Blasco H
Mol Neurobiol; 2017 Sep; 54(7):5361-5374. PubMed ID: 27590138
[TBL] [Abstract][Full Text] [Related]
9. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics evidences plasma and serum biomarkers differentiating two heavy pig breeds.
Bovo S; Mazzoni G; Galimberti G; Calò DG; Fanelli F; Mezzullo M; Schiavo G; Manisi A; Trevisi P; Bosi P; Dall'Olio S; Pagotto U; Fontanesi L
Animal; 2016 Oct; 10(10):1741-8. PubMed ID: 27055632
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics in amyotrophic lateral sclerosis: how far can it take us?
Blasco H; Patin F; Madji Hounoum B; Gordon PH; Vourc'h P; Andres CR; Corcia P
Eur J Neurol; 2016 Mar; 23(3):447-54. PubMed ID: 26822316
[TBL] [Abstract][Full Text] [Related]
12. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis.
Bjornevik K; Zhang Z; O'Reilly ÉJ; Berry JD; Clish CB; Deik A; Jeanfavre S; Kato I; Kelly RS; Kolonel LN; Liang L; Marchand LL; McCullough ML; Paganoni S; Pierce KA; Schwarzschild MA; Shadyab AH; Wactawski-Wende J; Wang DD; Wang Y; Manson JE; Ascherio A
Neurology; 2019 Apr; 92(18):e2089-e2100. PubMed ID: 30926684
[TBL] [Abstract][Full Text] [Related]
13. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial.
Rafiq MK; Lee E; Bradburn M; McDermott CJ; Shaw PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):478-84. PubMed ID: 26161993
[TBL] [Abstract][Full Text] [Related]
14. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics.
Lawton KA; Brown MV; Alexander D; Li Z; Wulff JE; Lawson R; Jaffa M; Milburn MV; Ryals JA; Bowser R; Cudkowicz ME; Berry JD;
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):362-70. PubMed ID: 24984169
[TBL] [Abstract][Full Text] [Related]
15. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model.
Sunyach C; Michaud M; Arnoux T; Bernard-Marissal N; Aebischer J; Latyszenok V; Gouarné C; Raoul C; Pruss RM; Bordet T; Pettmann B
Neuropharmacology; 2012 Jun; 62(7):2346-52. PubMed ID: 22369784
[TBL] [Abstract][Full Text] [Related]
16. Targeted metabolomics reveals reduced levels of polyunsaturated choline plasmalogens and a smaller dimethylarginine/arginine ratio in the follicular fluid of patients with a diminished ovarian reserve.
de la Barca JMC; Boueilh T; Simard G; Boucret L; Ferré-L'Hotellier V; Tessier L; Gadras C; Bouet PE; Descamps P; Procaccio V; Reynier P; May-Panloup P
Hum Reprod; 2017 Nov; 32(11):2269-2278. PubMed ID: 29040513
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
[TBL] [Abstract][Full Text] [Related]
18. Urinary Metabolomic Profiling in Chronic Hepatitis B Viral Infection Using Gas Chromatography/Mass Spectrometry.
Dittharot K; Jittorntam P; Wilairat P; Sobhonslidsuk A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):741-748. PubMed ID: 29582629
[TBL] [Abstract][Full Text] [Related]
19. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
